Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

A recently developed treatment strategy for lung cancer that combines immune checkpoint inhibitors with chemotherapy has been applied as a standard treatment for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), and it has improved the outcomes of chemotherapy. Maintenance treatmen...

Full description

Bibliographic Details
Main Authors: Wongeun Lee, Dong Kwon Kim, Chun-Bong Synn, Hee Kyu Lee, Sungho Park, Dong-Sik Jung, Yewon Choi, Jae Hwan Kim, Youngseon Byeon, Young Seob Kim, Seul Lee, Soyeon Lee, Yunjoo Joo, Eun Ji Lee, Mi Ran Yun, Seong Gu Heo, Wookyeom Yang, Ji Eun Jung, Eun Kyung Kim, Jooyeon Park, June Dong Park, Doo Jae Lee, Hyeon-Woo Kim, Sun Min Lim, Min Hee Hong, Beung-Chul Ahn, Jii Bum Lee, Kyoung-Ho Pyo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
AXL receptor tyrosine kinase
non-small cell lung cancer
chemotherapy
immunotherapy
epithelial-mesenchymal transition
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.821391/full

Similar Items

Similar Items